drugset
drugset / Trial / NCT06449586

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

NCT06449586 ↗

Phase 3 Active not recruiting 250 enrolled Ruijin Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.

Timeline

Start
2024-07-01
Primary completion
2026-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Letermovir Small molecule — —

Indications

hematopoietic and lymphoid system neoplasm